The looming threat of bedaquiline resistance in tuberculosis
- 4 June 2020
- journal article
- letter
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 55 (6), 2000718
- https://doi.org/10.1183/13993003.00718-2020
Abstract
The first step to reduce the risk of creating an epidemic of bedaquiline-resistant TB entails addressing the lack of access to rapid fluoroquinolone drug susceptibility testing in a high proportion of MDR-/RR-TB in low- and middle-income countries https://bit.ly/2KbtyZ3This publication has 7 references indexed in Scilit:
- Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patientsEuropean Respiratory Journal, 2020
- Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countriesEClinicalMedicine, 2020
- Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievementsRespiratory Medicine, 2019
- Multidrug-resistant tuberculosisThe Lancet, 2019
- A Trial of a Shorter Regimen for Rifampin-Resistant TuberculosisThe New England Journal of Medicine, 2019
- Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosisPLOS ONE, 2017
- 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trialThe Lancet, 2012